Prominently, the efficacy of checkpoint-inhibitor therapy in a small subgroup of PDAC patients with MMR-deficiency has initiated the era of personal medicine for pancreatic carcinoma patients and introduced the first FDA-approved treatment targeting a cellular stromal component. Here, MRC1 is linked to exocrine pancreatic carcinoma.